AIM ImmunoTech(AIM)

Search documents
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
Globenewswire· 2025-02-26 13:30
Core Insights - AIM ImmunoTech Inc. has appointed David Chemerow as an Independent Director to its Board of Directors, effective immediately [1] - Mr. Chemerow has over 40 years of experience in finance, accounting, and operations across various industries, including significant roles at Comscore, Inc. and Rentrak Corporation [2] - The Chairman of AIM's Board, William Mitchell, expressed confidence in Mr. Chemerow's leadership and financial acumen, which are expected to contribute to AIM's mission [6] Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for treating cancers, immune disorders, and viral diseases, including COVID-19 [7] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials for significant health issues [7]
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Globenewswire· 2025-02-25 13:30
Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”). Several subjects from Pha ...
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Globenewswire· 2025-02-11 13:45
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)Watch the “What This Means” segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced th ...
AIM ImmunoTech Releases Virtual Investor "What This Means Segment"
Newsfilter· 2025-02-11 13:45
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer ("DURIPANC")Watch the "What This Means" segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that AIM CEO ...
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
Globenewswire· 2025-02-11 13:30
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral ...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
GlobeNewswire News Room· 2025-02-07 13:50
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s antiviral priority development pipeline. AIM has engaged Amarex Clinical Research (“Amarex”), its Clinical Research Organization (“CRO”), with the application and eventual management of a follow-up Investigational New Drug (“IND”) application for the study of a potential ...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
Newsfilter· 2025-02-07 13:50
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company's antiviral priority development pipeline. AIM has engaged Amarex Clinical Research ("Amarex"), its Clinical Research Organization ("CRO"), with the application and eventual management of a follow-up Investigational New Drug ("IND") application for the study of a potential avian inf ...
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Newsfilter· 2025-02-05 13:00
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently OCALA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintato ...
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
Newsfilter· 2025-01-23 13:50
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final Clinical Study Results for the "Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions" ("AMP-518") was posted yesterday to ClinicalTrials.gov (See: NCT05592418). CEO Thomas K. Equels stated: "The results of AMP-518 support AIM's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of f ...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
Globenewswire· 2025-01-22 13:30
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response, offering potential therapeutic benefits for people with ME/CFS or Post-COVID chronic fatigue OCALA, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today offered commentary on a new article ...